Gary W Miller

List of Publications by Year
in descending order

171 papers	11,446 citations	28242 55 h-index	31818 101 g-index
183 all docs	183 docs citations	183 times ranked	11735 citing authors

#	Article	IF	Citations
1	Preventing Parkinsonâ€™s Disease: An Environmental Agenda. Journal of Parkinson's Disease, 2022, 12, 45-68.	1.5	45
2	Highâ€Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. Hepatology Communications, 2022, 6, 965-979.	2.0	11
3	Editor-in-Chief response to â€œFAIR-ifying the <i>Exposome</i> Journal: templates for chemical structures and transformationsâ€• Exposome, 2022, 2, .	1.2	0
4	An exposomic framework to uncover environmental drivers of aging. Exposome, 2022, 2, osac002.	1.2	12
5	Integrating Environment and Aging Research: Opportunities for Synergy and Acceleration. Frontiers in Aging Neuroscience, 2022, 14, 824921.	1.7	14
6	The Interplay of Environmental Exposures and Mental Health: Setting an Agenda. Environmental Health Perspectives, 2022, 130, 25001.	2.8	18
7	GAIT-GM integrative cross-omics analyses reveal cholinergic defects in a C. elegans model of Parkinsonâ€™s disease. Scientific Reports, 2022, 12, 3268.	1.6	2
8	Merging the exposome into an integrated framework for â€œomicsâ€•sciences. IScience, 2022, 25, 103976.	1.9	18
9	The Exposome and Toxicology: A Winâ€“Win Collaboration. Toxicological Sciences, 2022, 186, 1-11.	1.4	20
10	Evaluating Coâ€occurrence as a Criterion for Identification of Undocumented Xenobiotic Exposures in Human Metabolomics. FASEB Journal, 2022, 36, .	0.2	0
11	Cross-species metabolomic analysis of tau- and DDT-related toxicity. , 2022, 1, .		5
12	Using technology and exposomics to understand and address sleep health disparities. , 2022, , .		0
13	Using the exposome to understand environmental contributors to psychiatric disorders. Neuropsychopharmacology, 2021, 46, 263-264.	2.8	6
14	Exposome: a new field, a new journal. Exposome, 2021, 1, .	1.2	9
15	Genetic or Toxicant-Induced Disruption of Vesicular Monoamine Storage and Global Metabolic Profiling in<i>Caenorhabditis elegans</i>. Toxicological Sciences, 2021, 180, 313-324.	1.4	6
16	ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 139-158.	3.9	21
17	The Emergence and Future of Public Health Data Science. Public Health Reviews, 2021, 42, 1604023.	1.3	11
18	Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo. Journal of Neurochemistry, 2021, 158, 960-979.	2.1	22

#	ARTICLE	IF	CITATIONS
19	Utilizing a Biology-Driven Approach to Map the Exposome in Health and Disease: An Essential Investment to Drive the Next Generation of Environmental Discovery. Environmental Health Perspectives, 2021, 129, 85001.	2.8	20
20	A scalable workflow to characterize the human exposome. Nature Communications, 2021, 12, 5575.	5.8	31
21	Large scale enzyme based xenobiotic identification for exposomics. Nature Communications, 2021, 12, 5418.	5.8	18
22	Towards a comprehensive characterisation of the human internal chemical exposome: Challenges and perspectives. Environment International, 2021, 156, 106630.	4.8	39
23	Restoration of Noradrenergic Function in Parkinsonâ€™s Disease Model Mice. ASN Neuro, 2021, 13, 175909142110097.	1.5	7
24	Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters. Chemical Research in Toxicology, 2021, 34, 1256-1264.	1.7	12
25	Integrating the exposome into a multi-omic research framework. Exposome, 2021, 1, .	1.2	6
26	Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases. Hepatology, 2020, 71, 352-362.	3.6	18
27	Vesicular monoamine transporter 2 mediates fear behavior in mice. Genes, Brain and Behavior, 2020, 19, e12634.	1.1	10
28	Highâ€resolution metabolomic profiling of Alzheimerâ€™s disease in plasma. Annals of Clinical and Translational Neurology, 2020, 7, 36-45.	1.7	42
29	Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: An untargeted metabolomics approach. Environment International, 2020, 134, 105220.	4.8	110
30	Metformin rescues Parkinsonâ€™s disease phenotypes caused by hyperactive mitochondria. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26438-26447.	3.3	95
31	The exposome: purpose, definitions, and scope. , 2020, , 1-26.		2
32	Nurturing science. , 2020, , 53-80.		0
33	Measuring exposures and their impacts: practical and analytical. , 2020, , 107-129.		0
34	Sampling interstitial fluid from human skin using a microneedle patch. Science Translational Medicine, 2020, 12, .	5.8	150
35	Differences in plasma metabolites related to Alzheimer's disease, <i>APOE</i> Îµ4 status, and ethnicity. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12025.	1.8	19
36	Using the exposome to address geneâ€“environment interactions in kidney disease. Nature Reviews Nephrology, 2020, 16, 621-622.	4.1	7

#	Article	IF	Citations
37	Pathways and networks. , 2020, , 155-179.		0
38	The exposome and health: Where chemistry meets biology. Science, 2020, 367, 392-396.	6.0	499
39	Unsupervised dimensionality reduction for exposome research. Current Opinion in Environmental Science and Health, 2020, 15, 32-38.	2.1	10
40	The exposome â€“ a new approach for risk assessment. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 3-23.	0.9	45
41	The Exposome: Pursuing the Totality of Exposure. , 2020, , 3-10.		2
42	Innovation and the exposome. , 2020, , 131-154.		0
43	The exposome in the future. , 2020, , 237-267.		0
44	The Exposome: Molecules to Populations. Annual Review of Pharmacology and Toxicology, 2019, 59, 107-127.	4.2	144
45	The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance. ACS Chemical Neuroscience, 2019, 10, 3927-3938.	1.7	53
46	Reproducibility Revisited: Reflections of an Editor. Toxicological Sciences, 2019, 169, 315-316.	1.4	1
47	The Metabolome: a Key Measure for Exposome Research in Epidemiology. Current Epidemiology Reports, 2019, 6, 93-103.	1.1	57
48	Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens. Neuropsychopharmacology, 2019, 44, 1445-1455.	2.8	24
49	Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicological Sciences, 2019, 169, 280-292.	1.4	16
50	Networks at the nexus of systems biology and the exposome. Current Opinion in Toxicology, 2019, 16, 25-31.	2.6	13
51	Multigenerational metabolic profiling in the Michigan PBB registry. Environmental Research, 2019, 172, 182-193.	3.7	17
52	Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain. Brain Research, 2019, 1702, 85-95.	1.1	17
53	HERCULES: An Academic Center to Support Exposome Research. , 2019, , 339-348.		2
54	The metabolome: A key measure for exposome research in epidemiology. Current Epidemiology Reports, 2019, 6, 93-103.	1.1	18

#	Article	IF	Citations
55	Human Suction Blister Fluid Composition Determined Using High-Resolution Metabolomics. Analytical Chemistry, 2018, 90, 3786-3792.	3.2	72
56	NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate. Journal of Neuroscience Research, 2018, 96, 1324-1335.	1.3	18
57	Bioinspired Honokiol Analogs and Their Evaluation for Activity on the Norepinephrine Transporter. Molecules, 2018, 23, 2536.	1.7	1
58	ToxSci at 20. Toxicological Sciences, 2018, 161, 3-4.	1.4	0
59	A Farewell to Harms: The Audacity to Design Safer Products. Toxicological Sciences, 2018, 161, 211-213.	1.4	1
60	Systematic Reviews in Toxicology. Toxicological Sciences, 2018, 163, 335-337.	1.4	12
61	Ubiquitous Flame-Retardant Toxicants Impair Spermatogenesis in a Human Stem Cell Model. IScience, 2018, 3, 161-176.	1.9	24
62	Toxicology and Tributaries in Texas. Toxicological Sciences, 2018, 162, 3-4.	1.4	0
63	2018 Toxicological Sciences Paper of the Year: Assessing Fibrogenesis Using 3D-Printed Liver Tissues. Toxicological Sciences, 2018, 162, 339-340.	1.4	0
64	Per- and polyfluoroalkyl substances impact human spermatogenesis in a stem-cell-derived model. Systems Biology in Reproductive Medicine, 2018, 64, 225-239.	1.0	35
65	Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2253-E2262.	3.3	101
66	2017 Toxicological Sciences Paper of the Year. Toxicological Sciences, 2017, 156, 313-314.	1.4	0
67	The International Reach of Toxicology. Toxicological Sciences, 2017, 157, 274-275.	1.4	2
68	From the exposome to mechanistic understanding of chemical-induced adverse effects. Environment International, 2017, 99, 97-106.	4.8	146
69	Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. Journal of Chemical Neuroanatomy, 2017, 83-84, 82-90.	1.0	28
70	Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. European Journal of Neuroscience, 2017, 45, 20-33.	1.2	85
71	Science, Societies, and Society. Toxicological Sciences, 2017, 156, 2-3.	1.4	17
72	The Exposome Paradigm in Human Health: Lessons from the Emory Exposome Summer Course. Environmental Health Perspectives, 2017, 125, 064502.	2.8	25

#	Article	IF	Citations
73	Preprints in Toxicology. Toxicological Sciences, 2017, 155, 300-301.	1.4	2
74	A Golden Anniversary for the National Institute of Environmental Health Sciences. Toxicological Sciences, 2016, 154, 200-201.	1.4	0
75	Three Years After. Toxicological Sciences, 2016, 152, 262-263.	1.4	0
76	The Importance of the Biological Impact of Exposure to the Concept of the Exposome. Environmental Health Perspectives, 2016, 124, 1504-1510.	2.8	72
77	In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS ONE, 2016, 11, e0150602.	1.1	28
78	More than Manuscripts: Reproducibility, Rigor, and Research Productivity in the Big Data Era. Toxicological Sciences, 2016, 149, 275-276.	1.4	20
79	The Literature of Science. Toxicological Sciences, 2016, 153, 2-3.	1.4	2
80	Selective Enhancement of Dopamine Release in the Ventral Pallidum of Methamphetamine-Sensitized Mice. ACS Chemical Neuroscience, 2016, 7, 1364-1373.	1.7	30
81	Society of Toxicology Board of Publications Best Paper Award for 2016. Toxicological Sciences, 2016, 150, 259-260.	1.4	0
82	Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. Toxicological Sciences, 2016, 153, 79-88.	1.4	38
83	Toxicology: Cajun Style. Toxicological Sciences, 2016, 150, 2-2.	1.4	0
84	Making Data Accessible: The Dryad Experience. Toxicological Sciences, 2016, 149, 2-3.	1.4	11
85	Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Experimental Neurology, 2016, 275, 17-24.	2.0	16
86	Letters from Science Camp. Toxicological Sciences, 2015, 147, 301-301.	1.4	0
87	Developmental pesticide exposure reproduces features of attention deficit hyperactivity disorder. FASEB Journal, 2015, 29, 1960-1972.	0.2	105
88	Selective expression of Parkinson's disease-related<i>Leucine-rich repeat kinase 2</i>G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Human Molecular Genetics, 2015, 24, 5299-5312.	1.4	42
89	Young Investigators in Toxicology: Is There a Crisis?. Toxicological Sciences, 2015, 145, 2-4.	1.4	1
90	Society of Toxicology Board of Publications Best Paper Award for 2015. Toxicological Sciences, 2015, 144, 206-207.	1.4	0

#	Article	IF	Citations
91	Data Sharing in Toxicology: Beyond Show and Tell. Toxicological Sciences, 2015, 143, 3-5.	1.4	13
92	Increased Vesicular Monoamine Transporter 2 (VMAT2; <i>Slc18a2</i>) Protects against Methamphetamine Toxicity. ACS Chemical Neuroscience, 2015, 6, 790-799.	1.7	56
93	Reference Standardization for Mass Spectrometry and High-resolution Metabolomics Applications to Exposome Research. Toxicological Sciences, 2015, 148, 531-543.	1.4	186
94	<i>Toxicological Sciences</i>: Measuring the True Impact of the Journal. Toxicological Sciences, 2015, 147, 2-4.	1.4	4
95	Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiology of Disease, 2015, 74, 66-75.	2.1	119
96	VMAT2 and Parkinsonâ€™s disease: harnessing the dopamine vesicle. Expert Review of Neurotherapeutics, 2014, 14, 1115-1117.	1.4	40
97	Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9977-9982.	3.3	160
98	Contemporary Reviews in Toxicology. Toxicological Sciences, 2014, 142, 4-5.	1.4	4
99	The 53rd Annual Meeting of the Society of Toxicology . . . From Phoenix, Arizona. Toxicological Sciences, 2014, 138, 1-2.	1.4	1
100	Green Chemistry as a Leadership Opportunity for Toxicology: We Must Take the Wheel. Toxicological Sciences, 2014, 141, 4-5.	1.4	12
101	Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. Neurobiology of Disease, 2014, 67, 191-202.	2.1	94
102	The vesicular monoamine transporter 2: An underexplored pharmacological target. Neurochemistry International, 2014, 73, 89-97.	1.9	52
103	Improving Reproducibility in Toxicology. Toxicological Sciences, 2014, 139, 1-3.	1.4	42
104	A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 219-228.	2.1	27
105	The Nature of Nurture: Refining the Definition of the Exposome. Toxicological Sciences, 2014, 137, 1-2.	1.4	350
106	Ch-Ch-Ch-Changes. Toxicological Sciences, 2014, 140, 1-2.	1.4	2
107	Rotenone and paraquat perturb dopamine metabolism: A computational analysis of pesticide toxicity. Toxicology, 2014, 315, 92-101.	2.0	44
108	Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology, 2014, 76, 97-105.	2.0	58

#	Article	IF	Citations
109	The Exposome. , 2014, , 1-12.		19
110	Vesicular Integrity in Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2013, 13, 362.	2.0	36
111	RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-ÎºB signaling in dopaminergic cells. Neurobiology of Disease, 2013, 54, 264-279.	2.1	16
112	Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: Role of dopamine handling in neurotoxicity. Experimental Neurology, 2013, 241, 138-147.	2.0	53
113	Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19561-19566.	3.3	75
114	Editorial: A Toxicological Transition. Toxicological Sciences, 2013, 135, 261-262.	1.4	0
115	Research on the Premotor Symptoms of Parkinsonâ€™s Disease: Clinical and Etiological Implications. Environmental Health Perspectives, 2013, 121, 1245-1252.	2.8	68
116	Determinants of buildup of the toxic dopamine metabolite <scp>DOPAL</scp> in Parkinson's disease. Journal of Neurochemistry, 2013, 126, 591-603.	2.1	169
117	Association between polychlorinated biphenyls and Parkinson's disease neuropathology. NeuroToxicology, 2012, 33, 1298-1304.	1.4	64
118	Transport behavior of functionalized multi-wall carbon nanotubes in water-saturated quartz sand as a function of tube length. Water Research, 2012, 46, 4521-4531.	5.3	59
119	A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport. Journal of Neuroscience Methods, 2012, 209, 357-366.	1.3	21
120	Industrial toxicants and Parkinson's disease. NeuroToxicology, 2012, 33, 178-188.	1.4	121
121	Parkinson's disease and the environment: Beyond pesticides. NeuroToxicology, 2012, 33, 585.	1.4	12
122	25-Hydroxyvitamin D Depletion Does Not Exacerbate MPTP-Induced Dopamine Neuron Damage in Mice. PLoS ONE, 2012, 7, e39227.	1.1	13
123	VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-9.	0.6	75
124	The internal state of medium spiny neurons varies in response to different input signals. BMC Systems Biology, 2010, 4, 26.	3.0	24
125	Behavioral phenotyping of mouse models of Parkinson's disease. Behavioural Brain Research, 2010, 211, 1-10.	1.2	147
126	Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity. Journal of Neuroscience, 2009, 29, 8103-8113.	1.7	241

#	Article	IF	Citations
127	Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons. Molecular Neurobiology, 2009, 39, 149-170.	1.9	171
128	Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals. Synapse, 2009, 63, 1133-1142.	0.6	24
129	Reduced vesicular storage of dopamine exacerbates methamphetamineâ€induced neurodegeneration and astrogliosis. Journal of Neurochemistry, 2008, 106, 2205-2217.	2.1	86
130	The effects of environmental neurotoxicants on the dopaminergic system: A possible role in drug addiction. Biochemical Pharmacology, 2008, 76, 569-581.	2.0	162
131	PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides, 2008, 42, 423-434.	0.9	64
132	Disruption of dopamine transport by DDT and its metabolites. NeuroToxicology, 2008, 29, 682-690.	1.4	42
133	Developmental heptachlor exposure increases susceptibility of dopamine neurons to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in a gender-specific manner. NeuroToxicology, 2008, 29, 855-863.	1.4	49
134	Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends in Neurosciences, 2008, 31, 303-308.	4.2	101
135	Parkinson's disease and pesticides: a toxicological perspective. Trends in Pharmacological Sciences, 2008, 29, 322-329.	4.0	275
136	Treadmill Gait Analysis Does Not Detect Motor Deficits in Animal Models of Parkinson's Disease or Amyotrophic Lateral Sclerosis. Journal of Motor Behavior, 2008, 40, 568-577.	0.5	44
137	Computational Systems Analysis of Dopamine Metabolism. PLoS ONE, 2008, 3, e2444.	1.1	62
138	Divergent Mechanisms of Paraquat, MPP+, and Rotenone Toxicity: Oxidation of Thioredoxin and Caspase-3 Activation. Toxicological Sciences, 2007, 95, 163-171.	1.4	118
139	Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Experimental Neurology, 2007, 204, 619-630.	2.0	120
140	Use-dependent behavioral and neurochemical asymmetry in MPTP mice. Neuroscience Letters, 2007, 418, 213-216.	1.0	13
141	Obligatory Role for Complex I Inhibition in the Dopaminergic Neurotoxicity of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicological Sciences, 2007, 95, 196-204.	1.4	109
142	Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration. Journal of Neuroscience, 2007, 27, 8138-8148.	1.7	346
143	Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 070214184024016-???.	2.1	265
144	Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB Journal, 2006, 20, 1695-1697.	0.2	188

#	Article	IF	Citations
145	Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behavioural Brain Research, 2006, 172, 97-105.	1.2	113
146	Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicology and Applied Pharmacology, 2006, 211, 188-197.	1.3	99
147	Polychlorinated Biphenylâ€"Induced Reduction of Dopamine Transporter Expression as a Precursor to Parkinson's Diseaseâ€"Associated Dopamine Toxicity. Toxicological Sciences, 2006, 92, 490-499.	1.4	94
148	Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone. Toxicological Sciences, 2005, 88, 193-201.	1.4	215
149	Perinatal Heptachlor Exposure Increases Expression of Presynaptic Dopaminergic Markers in Mouse Striatum. NeuroToxicology, 2005, 26, 721-728.	1.4	53
150	Reduced MPTP toxicity in noradrenaline transporter knockout mice. Journal of Neurochemistry, 2004, 91, 1116-1124.	2.1	76
151	Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels. Toxicology Letters, 2004, 148, 29-40.	0.4	89
152	DNA Microarrays to Analyze Gene Expression in Animals with Altered Transporter Expression. , 2003, 227, 61-70.		0
153	Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Experimental Neurology, 2002, 178, 80-90.	2.0	164
154	l-DOPA Does Not Cause Neurotoxicity in VMAT2 Heterozygote Knockout Mice. NeuroToxicology, 2002, 23, 611-619.	1.4	20
155	Acute Mitochondrial and Chronic Toxicological Effects of 1-Methyl-4-Phenylpyridinium in Human Neuroblastoma Cells. NeuroToxicology, 2002, 23, 569-580.	1.4	28
156	Forced Nonuse in Unilateral Parkinsonian Rats Exacerbates Injury. Journal of Neuroscience, 2002, 22, 6790-6799.	1.7	136
157	Decreased Ethanol Preference and Consumption in Dopamine Transporter Female Knock-Out Mice. Alcoholism: Clinical and Experimental Research, 2002, 26, 758-764.	1.4	46
158	Forced Limb-Use Effects on the Behavioral and Neurochemical Effects of 6-Hydroxydopamine. Journal of Neuroscience, 2001, 21, 4427-4435.	1.7	331
159	Dopamine Transporter and Vesicular Monoamine Transporter Knockout Mice: Implications for Parkinson's Disease. , 2001, 62, 179-190.		9
160	Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neuroscience, 2000, 3, 465-471.	7.1	435
161	Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice. Journal of Neuroscience, 1999, 19, 2424-2431.	1.7	229
162	Immunocytochemical localization of the dopamine transporter in human brain. , 1999, 409, 38-56.		282

#	Article	IF	Citations
163	Dopamine transporters and neuronal injury. Trends in Pharmacological Sciences, 1999, 20, 424-429.	4.0	313
164	Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease. Experimental Neurology, 1999, 156, 138-148.	2.0	174
165	Cocaine self-administration in dopamine-transporter knockout mice. Nature Neuroscience, 1998, 1, 132-137.	7.1	463
166	[27] Generation of transporter-specific antibodies. Methods in Enzymology, 1998, 296, 407-422.	0.4	8
167	Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice. Journal of Neurochemistry, 1998, 70, 1973-1978.	2.1	148
168	Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine. Neuron, 1997, 19, 1285-1296.	3.8	345
169	Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Annals of Neurology, 1997, 41, 530-539.	2.8	190
170	Neurotoxicity of Manufactured Nanoparticles. , 0, , 405-428.		0
171	Analytical strategies for chemical exposomics: exploring limits and feasibility. Exposome, 0, , .	1.2	7